News & Achievements

2019-03-12

MCR Technology published in Nature Immunology

Deciphering CD4+ T cell specificity using novel MHC–TCR chimeric receptors Nature Immunology.

2018-04-02

Baselaunch 2018

Tepthera was selected as one of four winners out of 112 participants from over 30 countries. Read more about this on www.baselaunch.ch.

2018-04-02

CTI grant 2017

Tepthera received funding form the Commission for Technology and Innovation to further develop its technology and to bring it to the clinic.

2018-04-20

Venture Kick 2016

Personalized cancer vaccines (Biotech): Personalized therapeutic cancer vaccines based on novel targets discovered using our proprietary MCR screening platform. This technology allows fast and effective identification of cancer specific peptides and provides a strong basis for efficient therapeutic vaccine development.

2018-04-02

Spark Award 2015

Teptheras MCR technology was selected to be the most promising invention of 2014 that was registered for a patent. Read more about this on www.ethz.ch.